指南与共识药物不良反应与药物警戒

有效药物警戒体系建设:EFPIA-IPVG 共识建议

Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations.
指南 / 共识 · Drug Saf · 2020-12-08

欧洲制药工业协会联合会国际药物警戒组(EFPIA-IPVG)基于跨国药企在多国满足药物警戒监管要求的经验,提出与协调标准一致的共识建议,用于指导各国药物警戒体系的建立与分步实施,尤其面向基础设施和资源有限的国家,并获 EFPIA 成员认可。

要点

  • 建议与ICH协调标准一致,支持药物警戒体系关键组件的分步实施。
  • 重点面向基础设施与资源有限、监管框架尚不完善的国家。
  • 各国要求偏离国际标准会增加企业负担,且患者安全获益未必明显。

核心结论

  • EFPIA-IPVG 提出与协调标准一致的共识建议,支持各国建立并分步实施药物警戒体系的关键组件,尤其适用于基础设施和资源有限的国家。
  • 这些建议获 EFPIA 成员认可,旨在帮助国家监管机构建设或进一步完善药物警戒体系。

研究设计与样本

  • 本文为 EFPIA-IPVG 制定的共识建议综述,制定机构为欧洲制药工业协会联合会(EFPIA)国际药物警戒组(IPVG)。
  • 建议基于全球制药企业在多国履行药物警戒监管义务中积累的经验,并获 EFPIA 成员认可。

主要发现

  • 全球制药企业需应对从欠优框架到资源优化高效体系等多种药物警戒体系,积累了广泛经验。
  • 部分国家的要求偏离国际公认标准,增加相关方复杂性并加重负担,而患者安全获益未必明显。
  • 在 NRA 属于 ICH 成员的国家,安全管理要求通常与 ICH 指南一致。

关键数值与推荐

  • 建议与协调标准一致,用于药物警戒体系关键组件的建立与分步实施。
  • 各国药物警戒框架可按 WHO 全球基准工具评估,范围从欠优框架到资源优化高效体系。

临床怎么用

  • 临床药学相关方可将该共识作为理解药物警戒体系关键组件与分步实施的参考框架。
  • 在跨国或多国持有产品许可的企业,可参照协调标准应对各国药物警戒要求的差异。

局限性

  • 本文为共识建议综述,未报告具体研究设计、样本量或定量结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmaceutical legislation provides a legal framework to ensure the safe and effective use of medicines. This framework requires national regulatory authorities (NRAs) to establish and maintain a pharmacovigilance system (PV system) stating and enforcing the regulatory commitments that key stakeholders, including marketing authorisation holders (MAHs), are required to fulfil. In recent years, national legislative bodies and NRAs across the world have issued a significant amount of legislation and guidance enforcing the obligation to perform pharmacovigilance activities. In countries where the NRA is a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), safety management requirements are generally consistent with ICH guidelines. In a number of countries beyond this scope, requirements may deviate from internationally agreed standards, adding a substantial complexity and increasing burden on the stakeholders involved, whilst the benefit for patients' safety may not be evident. Committed to fulfilling safety-regulatory obligations in any country where a product licence is held, global pharmaceutical companies have accumulated a broad and deep experience acquired whilst meeting the expectations of a large array of diverse PV systems across the world. These range from sub-optimal frameworks, according to the World Health Organization (WHO) Global Benchmarking Tool, to highly effective resource-optimised PV systems. In order to support countries creating or further developing their PV systems, especially where infrastructure and resources are limited, the European Federation of Pharmaceutical Industries and Associations (EFPIA) International Pharmacovigilance Group (IPVG) has developed consensus recommendations consistent with harmonised standards for the development and step-wise implementation of key PV system components. These recommendations endorsed by the EFPIA membership constitute the focus of this review article.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Peters T, Soanes N, Abbas M, et al. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations. Drug Saf. 2020. PMID: 33289904. doi:10.1007/s40264-020-01008-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。